

Babeş-Bolyai University
Faculty of Chemistry and Chemical Engineering
Doctoral School of Chemistry

***Wild-type* and tailored phenylalanine ammonia-
lyases for the synthesis of unnatural
L- and D-arylalanines**

PhD Thesis Abstract



PhD candidate: Alina FILIP
Scientific advisor: Prof. Habil. Dr. Csaba PAIZS

Cluj-Napoca
2019



„BABEŞ-BOLYAI“ UNIVERSITY
CLUJ-NAPOCA



FACULTY OF CHEMISTRY AND CHEMICAL ENGINEERING
Doctoral School of Chemistry

***Wild-type* and tailored phenylalanine ammonia-lyases for the synthesis of unnatural L- and D-arylalanines**

PhD Thesis Abstract

PhD candidate: Alina FILIP

Jury:

President: Prof. Dr. Florin-Dan IRIMIE – Faculty of Chemistry and Chemical Engineering, Babeş-Bolyai University, Cluj-Napoca

Scientific advisor: Prof. Habil. Dr. Csaba PAIZS – Faculty of Chemistry and Chemical Engineering, Babeş-Bolyai University, Cluj-Napoca

Reviewers: Prof. Dr. Nicolaie DRAGOŞ – Faculty of Biology and Geology, Babeş-Bolyai University, Cluj-Napoca.

Prof. Dr. Dan SCUTARU – Faculty of Chemical Engineering and Environmental Protection, Gheorghe Asachi Technical University, Iași.

Prof. Dr. Valentin ZAHARIA – Faculty of Pharmacy, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca

Public defense: 21st June 2019, Cluj-Napoca

Thesis Table of Contents

Table of Contents	3
List of abbreviations.....	9
Scientific activity	15
Introduction	17
Aims of the thesis.....	19
CHAPTER I. Systems of expression and purification	20
Subchapter A. Expression and purification of recombinant, <i>wild-type</i> and mutant forms of phenylalanine ammonia-lyase from <i>Petroselinum crispum</i>	20
I. A.1. Literature survey	20
I. A.1.1. Aromatic ammonia-lyases.....	20
I. A.1.2. Phenylalanine ammonia-lyases (PALs): sources and applications	21
I. A.1.3. The MIO electrophilic group and other characteristics of the catalytic site ...	22
I. A.1.4. The mechanism of action of phenylalanine ammonia-lyases	25
I. A.1.4.1. The E1cB type elimination	26
I. A.1.4.2. The Friedel-Crafts acylation	26
I. A.2. Results and discussion	27
I. A.2.1. Site-directed mutagenesis	27
I. A.2.2. Expression and purification of proteins	30
I. A.2.2.1. SDS-PAGE analysis	31
I. A.2.2.2. Steric exclusion chromatography.....	32
I. A.2.3. Analyzing thermal unfolding of <i>PcPAL</i> mutants using the Prometheus NT.48.....	33
I. A.3. Conclusions.....	36
I. A.4. Materials and methods.....	37
I. A.4.1. Gene, vectors and enzymes	37
I. A.4.2. Chemicals and materials	37
I. A.4.3. Equipment for genetics and microbiology, expression and purification of enzymes.....	37
I. A.4.4. Site-directed mutagenesis	38
I. A.4.5. Multiplication of competent XL1-Blue cells	41
I. A.4.6. Transformation in <i>E. coli</i> host cells, XL1-Blue	41
I. A.4.7. Plasmid isolation, DNA concentration and sequencing services	42
I. A.4.8. Multiplication of competent Rosetta (DE3) pLyS cells.....	42
I. A.4.9. Transformation in <i>E. coli</i> host cells, Rosetta (DE3) pLyS cells	42

I. A.4.10. Expression and purification of recombinant proteins (native and mutant forms)	44
I. A.4.10.1. Expression and purification of phenylalanine ammonia-lyase	44
I. A.4.10.2. Cell lysis	44
I. A.4.10.3. Ni-NTA affinity chromatography	44
I. A.4.10.4. Size-exclusion chromatography	45
I. A.4.10.5. Determination of protein concentration	47
I. A.4.10.6. SDS-PAGE	48
I. A.4.1.1. Determination of thermal stability with NanoDSF	48
Subchapter B. Obtaining mutant <i>PcPAL</i> variants without hexa histidine-tag in order to crystallize the protein in its most natural form	50
I. B.1. Literature survey. Proteases. Tobacco Etch Virus (TEV) protease	50
I. B.2. Results and discussion	52
I. B.2.1. Site-directed mutagenesis, plasmid isolation and the required transformation.....	52
I. B.2.2. Identification, expression and purification of the hexa histidine-tag <i>PcPAL wild-type</i> and mutant <i>PcPAL</i> variants with tag removal.....	53
I. B.2.3. Expression and purification of TEV S219V enzyme	54
I. B.2.4. The removal of 6xHis-tag from raw expression products of <i>PcPAL</i> through digestion with TEV S219V	56
I. B.2.5. Analysis of oligomerization state and purity of non-6xHis-tag enzymes by steric exclusion chromatography.....	57
I. B.2.6. Analyzing thermal unfolding of <i>PcPAL</i> mutants using the Prometheus NT.48.....	60
I. B.2.7. Crystallization of I460V <i>PcPAL</i> without His-tag	61
I. B.3. Conclusions.....	63
I. B. 4. Materials and methods	64
I. B.4.1. Host cells and plasmids	64
I. B.4.2. Site-directed mutagenesis, plasmid isolation and transformations	64
I. B.4.3. Expression and purification of the <i>PcPAL wild-type</i> and mutant <i>PcPAL</i> variants without His-tag	65
I. B.4.4. Expression and purification of TEV S219V enzyme	66
I. B.4.4.1. Cell lysis.....	66
I. B.4.4.2. Purification using Ni-NTA affinity chromatography.....	66
I. B.4.5. His-tag removal from <i>PcPAL</i> by digestion with TEV S219V	67
I. B.4.6. Western Blot analysis.....	68

Subchapter C. Expression and purification of new MIO enzymes from <i>Pseudomonas fluorescens</i> R124	69
I. C.1. Literature survey. MIO enzymes	69
I. C.2. Results and discussion	72
I. C.2.1. Expression and purification of aromatic phenylalanine 2,3-aminomutase (PAM), phenylalanine/histidine or tyrosine ammonia-lyase (XAL) and histidine ammonia-lyase (HAL) all isolated from <i>Pseudomonas fluorescens</i> R124.	72
I. C.2.1.1. Expression and purification of PAM, XAL and HAL.....	72
I. C.2.2. Melting temperatures (T_m) and global thermostability of <i>Pf</i> HAL, <i>Pf</i> XAL and <i>Pf</i> PAM enzymes.....	74
I. C.3. Conclusions.....	76
I. C.4. Materials and methods	77
I. C.4.1. Reagents. Equipment. Biological material	77
I. C.4.2. Fermentation and expression of <i>Pf</i> HAL, <i>Pf</i> XAL and <i>Pf</i> PAM of MIO enzymes from <i>Pseudomonas fluorescens</i> R124	77
I. C.4.3. SDS-PAGE and thermal characterization of the novel MIO-enzymes	77
CHAPTER II. Chemical synthesis and biotransformations mediated by <i>wt</i>- and <i>Pc</i>PAL mutant variants	78
Subchapter A. Chemical synthesis of styrylalanines as novel substrates for phenylalanine ammonia-lyase	78
II. A.1. Literature survey.....	78
II. A.1.1. Chemical Methods	78
II. A.1.2. Chemo-enzymatic methods	79
II. A.2. Results and discussion.....	82
II. A.2.1. Chemical synthesis of styrylalanines substrates <i>rac</i> - 1a-d and 2a-d	82
II. A.3. Conclusions	83
II. A.4. Materials and methods.....	83
II. A.4.1. Chemical reagents and equipment	83
II. A.4.2. Synthesis of (2 <i>E</i> ,4 <i>E</i>)-styrylacrylates 2a-d (Scheme 12).....	84
II. A.4.2.1 Synthesis of styrylacrylic esters 10a-d	84
II. A.4.2.2. Synthesis of styrylic alcohols 8a-d	84
II. A.4.2.3. Synthesis of the styrylacroleins 6a-d	85
II. A.4.2.4. Synthesis of the styrylacrylic esters 4a-d	85
II. A.4.2.5. Synthesis of the styrylacrylates 2a-d	85
II. A.4.3. Synthesis of racemic amino acids <i>rac</i> - 1a-d	86
II. A.4.3.1. Synthesis of halogenated compounds 9a-d	86

II. A.4.3.2. Synthesis of malonic acid derivatives 7a-d	86
II. A.4.3.3. Synthesis of dicarboxylic acid derivative 5a-d	86
II. A.4.3.4. Synthesis of racemic amino acids <i>rac-1a-d</i>	87
Subchapter B. Enlarging the substrate area of phenylalanine ammonia-lyase from <i>Petroselinum crispum</i> towards styrylalanines	88
II. B.1. Literature survey: Importance and applications of PALs and PAMs	88
II. B.2. Results and discussion	91
II. B.2.1. Initial studies on the activity of <i>PcPAL</i> and its F137X mutant variants towards styrylalanines	91
II. B.2.2. Enzyme kinetics.....	93
II. B.2.3. Kinetic resolution and synthetic applications	94
II. B.2.4. Rationalization of styrylalanines <i>rac-1a-d</i> reactions catalyzed by <i>PcPAL</i> mutant variants	97
II. B.2.5. L-arylalanines production from styrylacrylates 2a-d in 6 M NH ₃ solution with <i>PcPALs</i>	98
II. B.3. Conclusions	99
Subchapter C. Tailored mutants of phenylalanine ammonia-lyase from <i>Petroselinum crispum</i> for the synthesis of bulky L- and D-arylalanines	101
II. C.1. Literature survey. PAL biocatalysts capable of converting a series of valuable and sterically valuable L- and D-arylalanines	101
II. C.2. Results and Discussion	104
II. C.2.1. Rational design, stability and activity of mutant <i>PcPALs</i>	104
II. C.2.2. Testing of <i>PcPAL</i> single mutant variants in the elimination reaction of arylalanines <i>rac-1a,e-l</i>	105
II. C.2.3. Testing of <i>PcPAL</i> single mutant variants in the ammonia addition reactions onto 2a,e-l cinnamic acids.....	106
II. C.2.4. Testing of <i>PcPAL</i> double and triple mutants variants in the elimination (<i>rac-1a,e-l</i>) and addition reaction (2a, e-l).....	107
II. C.2.5. Optimizations on the type of biocatalyst used and the solubilization of the tested substrates.....	108
II. C.2.6. Preparative applicability of the <i>PcPAL</i> mediated biotransformations	109
II. C.2.7. Computational results and the thermal unfolding profile of <i>wild-type PcPAL</i> and F137A/I460V- <i>PcPAL</i> in the presence of high concentrations of ammonia.....	110
II. C.2.8. Synthetic applicability of tailored <i>PcPAL</i> mutants in preparative scale	113
II. C.3. Conclusions	115
II. C.4. Materials and methods for Subchapter B and Subchapter C.....	116

II. C.4.1. Materials and methods	116
II. C.4.2. Instrumentation	116
II. C.4.3. Enzyme activity measurements (K_M , v_{max} , k_{cat}) - Subchapter B.....	117
II. C.4.5. HPLC monitoring of the enzymatic reactions - Subchapter B	118
II. C.4.5.1. Determination of the conversion by HPLC.....	118
II. C.4.5.2. HPLC methods to determine the enantiomeric excess (ee) of D-1a-d .	119
II. C.4.5.3. Chiral HPLC analysis of the final products from F137V- <i>PcPAL</i> - catalyzed kinetic resolutions of <i>rac</i> - 1a-d	120
II. C.4.5.4. Representative chromatogram of L- 1a obtained on Chiralpak Zwiex (+) chiral column-HPLC.....	120
II. C.4.5.5. The ammonia removal reaction of <i>rac</i> - 1a-d to the preparative scale using <i>wt-PcPAL</i> and F137V- <i>PcPAL</i>	121
II. C.4.5.6. Investigation of the ammonia addition onto styrylacrylates 2a-d by the <i>PcPAL</i> variants.....	121
II. C.4.5.7. Preparation of sodium borohydride treated <i>wt-PcPAL</i>	121
II. C.4.6. Analytical methods in HPLC chromatography - Subchapter C.....	122
II. C.4.6.1. The method of analysis of thermal expansion under different concentrations of ammonia.....	122
II. C.4.6.2. Ammonia source optimization in case of ammonia addition onto 2f ...	122
II. C.4.6.3. Ammonia eliminations of <i>rac</i> - 1a,e-l under optimized conditions	122
II. C.4.6.4. Ammonia additions of 2a,e-k under optimized conditions.....	123
II. C.4.6.5. Preparative scale ammonia eliminations of <i>rac</i> - 1a,e-g	123
II. C.4.6.6. Preparative scale ammonia additions of 2a,e-g	124
II. C.4.7. HPLC monitoring of the enzymatic reactions - Subchapter C	124
II. C.4.7.1. Determination of conversion values by HPLC	124
II. C.4.7.2. HPLC methods to determine the enantiomeric excess (ee) of D-and L- 1a,e-l	125
II. C.4.8. Inhibitory effect of 2l in the ammonia elimination reaction of L-Phe catalysed by <i>wt-PcPAL</i>	125
General Conclusions	126
Supplement for thesis.....	128
References	160

Scientific activity

I. Articles on which the thesis is based on.

- 1. Filip A.,** ‡ Nagy E.Z.A., ‡ Tork S.D., Bánóczy G., Toşa M.I., Irimie F.D., Poppe L., Csaba P., Bencze L.C., Tailored mutants of phenylalanine ammonia-lyase from *Petroselinum crispum* for the synthesis of bulky L- and D-arylalanines, *ChemCatChem*, **2018**, *10*, 2627-2633. **IF 4.674**
ISSN 1867-3880
Relative score of influence = 1.899
- 2.** Csuka P., Juhász V., Kohári Sz., **Filip A.**, Varga A., Sátorhelyi P., Bencze P., Barton H.A., Paizs C., Poppe L., *Pseudomonas fluorescens* strain R124 encodes three different MIO-enzymes, *ChemBioChem*, **2018**, *19*, 411-418. **IF 2.774**
ISSN 1439-4227
Relative score of influence = 1.840
- 3.** Bencze L.C., ‡ **Filip A.**, ‡ Bánóczy G., Toşa M.I., Irimie F.D., Gellért Á., Poppe L., Paizs C., Expanding the substrate scope of phenylalanine ammonia-lyase from: *Petroselinum crispum* towards styrylalanines, *Organic and Biomolecular Chemistry*, **2017**, *15*, 3717-3727. **IF 3.423**
ISSN 1477-0520
Relative score of influence = 1.798
- 4.** Dima N.A., **Filip A.**, Bencze L.C., Oláh M., Sátorhelyi P., Vértessy B.G., Poppe L., Paizs C., Expression and purification of recombinant Phenylalanine ammonia-lyase from *Petroselinum crispum*, *Studia UBB Chemia*, **2016**, *LXI*, *2*, 21-34. **IF 0.244**
ISSN 1224-7154
Relative score of influence = 0.026
- 5. Filip A.**, Bencze L.C., Paizs C., Poppe L., Irimie F.D., MIO-enzyme toolbox: cloning, expression and purification of recombinant *RtPAL*, *Stud. Univ. Babeş-Bol. Sp. Iss.* **2015**, 39-43. BDI
Short communication

‡ These authors contributed equally to this work.

Key words: site directed mutagenesis, expression and purification, phenylalanine ammonia-lyase, *wild-type*, tailored mutants, MIO-enzymes, styrylalanines, arylalanines, biocatalysis, enzymatic kinetic resolution.

Introduction

Amino acids are the building blocks of proteins, a class of biomacromolecules with a wide range of functions. Furthermore, they are involved in different metabolic pathways of fundamental processes of living organisms such as, growth, development, reproduction, immune protection, cellular and organism homeostasis.^{1,2} Accordingly, the term “*bricks of life*” associated with amino acids is well justified.

The practical use of natural and unnatural amino acids in the production of biologically valuable products or intermediates of fine organic synthesis useful for various industries provides a continuous interest towards their production.

Natural amino acids are accessible through their isolation from biological sources or by chemical/biochemical synthesis. Thus, the alternative for their production is mostly determined by economical and sustainability factors. Unnatural amino acids can be obtained only by synthesis. Their chiral nature and structural complexity, but also their similarity with natural amino acids, guide their synthesis towards more active, selective, environmentally friendly, thus more efficient biocatalytic routes.

The use of enzymatic preparations, with different degree of purification level, is a well-established practice both in academic research and in industrial manufacturing. Their capacity to assist reactions catalytically, with high activity and selectivity, provides a solid base for clean synthetic procedures. Therefore, the use of biocatalysts is based on the dichotomic compromise between selectivity and promiscuity. The proper function of an enzyme has been optimized over millions of years/generations by repetitive mutation/selection cycles. Such enzymes function perfectly for their natural substrates. Obviously, their performances towards an unnatural substrate analogues, will be inferior. Therefore, in case if an alternative, enzymatic synthetic route is required, the biocatalyst must be adapted to the unnatural substrate analogue. This adaption process can be accomplished either through rational means, employed within this thesis, or directed evolution methods. Since, each one of them present advantages/disadvantages results in the complexity of independent variables, making the choice specific for the studied case.

The research described within this thesis aimed to adapt, through rational means, the functionality of phenylalanine ammonia-lyase originary from *Petroselinum crispum* (*PcPAL*) towards bulky substrates. The range of substrates accepted by *PcPAL* is limited, bulky biaryl, heteroaryl substrate analogues are poorly or not transformed by the enzyme. Modifications focusing on the hydrophobic region of the catalytic site of *PcPAL* increased its tolerance towards bulky L- and D-arylalanines.^{3,4}

Tailored mutants of *PcPAL* such as variant F137V/A, I460V/A, with single mutations⁵ or with multiple mutations such as F137V/L138V, F137V/I460V, F137A/I460V or F137V/L138V/I460V have shown considerable enhancement of their catalytic properties compared to the *wild-type* enzyme, in reactions with bulky substrates, such as styrylalanines, (4-methoxyphenyl)-, (4'-fluoro-[1,1'-biphenyl]-4-yl)-, ([1,1'-biphenyl]-4-yl)-, (naphthalen-2-yl)- and (5-phenylthiophen-2-yl) alanines and their corresponding aryl-acrylic derivatives yielding a wide range of L- and D-arylalanines.⁶

Besides the specific procedures of organic synthesis used for substrates preparation, the genetic engineering and microbiology techniques, providing the recombinant PAL variants, the biotransformations, yielding the L- and D-arylalanines, other instruments such as, computational studies and X-ray crystallography were also used to provide molecular level insights of the PAL-catalyzed processes. The obtained data open new perspectives on the rational design of the hydrophobic binding pocket of *PcPAL*.

Through the presented results, the thesis contributes to a better understanding of phenylalanine ammonia-lyase (PAL) originary from *Petroselinum crispum*, by extending its range of utility and providing particular methodological contributions to adaption process of the enzyme for non-natural substrates of interest.

Aims of the thesis

This thesis is structured in two main chapters: Systems of expression and purification (I) and Chemical synthesis of styrylalanines and biotransformations mediated by *wild-type* and *PcPAL* mutant variants (II). Each chapter is divided in three subchapters. Each subchapter is divided in: literature survey, materials and methods, results and discussion and conclusions.

1. Modification of the catalytic site of phenylalanine ammonia-lyase from *Petroselinum crispum* through genetic engineering in order to provide novel mutant variants with superior biocatalytic activity (Subchapter I A).
2. His-tag removal of several *PcPAL* mutant enzymes (I460V, F137A, F137A/I460V and Y110F/F137/I460V) using a TEV endopeptidase (Tobacco Etch Virus) in order to provide highly purified protein samples for crystallization studies (Subchapter I B).
3. Expression, isolation and purification of three novel MIO enzymes, phenylalanine 2,3-aminomutase (*PfPAM*), phenylalanine/histidine ammonia-lyase/tyrosine (*PfXAL*) and histidine ammonia-lyase (*PfHAL*) identified in the genome of the bacterium *Pseudomonas fluorescens* R124 (Subchapter I C).
4. Chemical synthesis of styrylalanines as novel substrates for phenylalanine ammonia-lyase (Subchapter II A).
5. The rational development, using site-directed mutagenesis, of useful *PcPAL* mutants F137/G/A/V-*PcPAL* for the stereoselective synthesis of L-styryl-alanines (Subchapter II B).
6. Synthesis of synthetically valuable, bulky L- and D-arylalanines through rationally designed *PcPAL* mutants, bearing single or multiple mutations of the hydrophobic substrate binding region (Subchapter IIC).

CHAPTER I. Systems of expression and purification

Subchapter A. Expression and purification of recombinant, *wild-type* and mutant forms of phenylalanine ammonia-lyase from *Petroselinum crispum*

I. A.2. Results and discussion

I. A.2.1. Site-directed mutagenesis

Site-directed mutagenesis is a fast and reliable method used to alterate in a desired way a gene at the level of the desired codon. Replacement of an amino acid with a desired one is accomplished by changing a nucleotide (or two/three nucleotides) of the original codon with the nuclotide/nucleotides corresponding to the new codon encoding the desired amino acid.

The sequence alteration is performed through PCR reaction (Polymerase Chain Reaction), using a pair of specifically designed mutagenic primers, which contain the desired nucleotide modification.⁶

Figure 1 shows the agarose 1% gel in which the spots corresponding to some polymerization products can be observed (as described) at about 8.000 base pairs.




Figure 1. Agarose gel electrophoresis of the PCR products products from the site-directed mutagenesis experiments: **1** – **pET-19b** vector harbouring the gene of *wt-PcPAL* (7817 kpb), **2** – PCR reactions performed for mutation for **F137V**, **3** – product of PCR reaction performed for mutation **F137A**, **4** – PCR reactions for mutation **F137G**, **L** – DNA Ladder.

The polymerization products have been successfully transformed into *E.coli* XL1Blue competent cells for plasmid storage, followed by extraction of the plasmid.

External sequencing services were used to confirm the presence of the desired mutations. Once the mutations were confirmed, the corresponding plasmids were transformed succesfully into expression host *E.coli* Rossetta (DE3) pLysS cells.

I. A.2.2. Expression and purification of proteins

For the expression of *wild-type* and mutant phenylalanine ammonia-lyases, *Escherichia coli* Rosetta (DE3) pLyS host cells harbouring the pET-19b_*PcPAL* (**Figure 2a** and **2b**) expression vector were used.⁷




Figure 2a. Plasmid map of pET-19b-*PcPAL*

```

MGHHHHHSGHIDDDDKHMLEMENGNGATTNGHVNGNGMDFCMKTEDPLY
WGIAAEAMTGSHLDEVKKMVAEYRKPVVKLGGETLTISQVAAISARDGSG
VTVELSEARAGVKASSDWMDSMNKGTDSYGVTTGFGATSHRRTKQGGA
LQKELIRFLNAGIFGNGSDNTLPHSATRAAMLVRINTLLQGYSGIRFEIL
EAITKFLNQNIPTCLPLRGTITASGDLVPLSYIAGLLTGRPNKAVGPTG
VILSPPEAFKLAGVEGGFFELQPK EGLALVNGTAVGSGMAMVLFANIL
AVLAEVMSAIFAEVMQGKPEFTDHLTHKHKHHPGQIEAAIMEHILDGSA
YVKAQKLHEMDPLQKPKQDRYALRTSPQWLGPQIEVIRSSSTKMIEREIN
SVNDNPLIDVSRNKAIHGGNFQGTPIGVSMDNTRLAIAAIGKLMFAQFSE
LVNDFYNNGLPSNLSGGRNPSLDYGFKGAEIAMASYCSELQFLANPVTNH
VQSAEQHNQDVNSLGLISSRKTSEAVEILKLMSTTFLVGLCQAIIDLRLHE
ENLKSTVKNTVSSVAKRVLTMGVNGLHPSRFCEKDLLRVVDREYIFAYI
DDPCSATYPLMQKLRQTLVEHALKNGDNERNLSTSI FQKIATFEDELKAL
LPKEVESARAALSEGNPAIPNRIEECRSYPLYKVRKELGTEYLTGEKVT
SPGEEFEKVFIAMSKGEIIDPLLESLESWNGAPLPIS-AEQ-LA-
PLGASKR
  
```

Figure 2b. The translation sequence of *wt-PcPAL* with the *N*-terminal 6xHis-tag (green) and the enterokinase cleavage site (cyan).

The protein expression was performed at 37 °C by inducing the culture medium with 0.5 mM IPTG (isopropyl β-D-1-thiogalactopyranoside) at OD₆₀₀ of 0.7-0.8, then followed by maintaining the cell mass at 25 °C overnight.

Purification was performed on a Ni-NTA affinity chromatography column as described in the manufacturer's protocol. The *PcPAL* protein with the *N*-terminal His-tag was eluted with 250 mM imidazole.

I. A.2.2.1. SDS-PAGE analysis

The steps of enzyme expression and purification were monitored by SDS-PAGE with Coomassie Blue R 250 staining.

In lane 13 of the 10% polyacrylamide gel (**Figure 3**) a pronounced band around 80 kDa corresponding to the *PcPAL* monomer, with a high purity can be observed.




Figure 3. SDS-PAGE 10% gel containing samples from the purification steps of *PcPAL* F137V. **1** – cells before induction, **2** – cells after induction, **3** – cell lysate, **4** – pellet of the cells lysate, **5** – supernatant after centrifugation of the lysate, ***6** – flow-through fraction from the Ni-NTA column, ***7** – fraction eluted with a weak saline solution (30 mM KCl and 50 mM HEPES), ***8** – fraction eluted with a strong saline solution (300 mM KCl and 50 mM HEPES), ***9** – fraction eluted with a weak saline solution (30 mM KCl and 50 mM HEPES), ***10** – molecular weight marker, ***11** – fraction eluted with 25 mM imidazole, ***12** – fraction eluted with 50 mM imidazole, ***13** – fraction eluted with 250 mM imidazole (pure protein fraction), ***14** – fraction eluted with 1 M imidazole, **15** – the fraction with the pure protein after dialysis and **16** – molecular weight marker.

*samples from the Ni-NTA affinity purification step

I. A.2.2.2. Size exclusion chromatography

The purity of each enzyme obtained, was analyzed by size exclusion chromatography (analytical column Superdex 200 5/150 GL). Preparative scale purification of the enzymes was performed (on a preparative column Superdex 200 10/300 GL) in order to perform kinetic studies, which require the use of biocatalysts with a high degree of purity.

For most of the *PcPAL* mutants obtained, the degree of purity was high. In **Figure 4** below, the chromatogram profile for the mutants *PcPAL* I460V- and *PcPAL* F137A/L138A/I460A can be observed.

According to the equation of the calibration curve determined in advance, the signal between 1.3–1.6 mL with a maximum intensity at 1.48 mL, corresponds to the tetrameric *PcPAL* enzyme with a molecular weight of approximately 320 kDa.




Figure 4. Representative chromatograms obtained by analyzing the purity and oligomerization state of the enzymes using the steric exclusion column Superdex 200 5/150 GL, **A.** *PcPAL* I460V, **B.** *PcPAL* F137A/L138A/I460A after the dialysis and concentration steps (3 mg/mL).

I. A.2.3. Analyzing thermal unfolding of *PcPAL* mutants using the Prometheus NT.48

Nano differential scanning fluorimetry (NanoDSF)⁸ was used to determine the protein stability of *wt-PcPAL* and its mutants by measuring the melting temperature (T_m). As a result of the mutation, enzymes can suffer significant changes, which can be observed by comparing the T_m value to that of the *wild-type* enzyme.

Table 1. Melting temperature (T_m) of *PcPAL* variants.

Entry	<i>PcPAL</i>	T_m (°C)
1	<i>wild-type</i>	75.1±0.2
2	L134A	70.2±0.5
3	L134V	72.6±0.2
4	F137G	74.2±0.3
5	F137A	76.2±0.2
6	F137V	73.5±0.4
7	L138A	72.3±0.2
8	L138V	68.4±0.3
9	L206A	72.6±0.8
10	L206V	74.4±0.5
11	L256A	72.9±0.7
12	L256V	73.1±0.5
13	I460A	51.3±0.8
14	I460V	74.2±0.2
15	F137A/I460V	74.4±0.4
16	F137A/ I460A	51.8±0.9
17	F137V/I460A	51.8±0.8
18	F137V/I460V	71.7±0.3
19	F137A/L138V	70.9±0.4
20	F137A/L138A	75.3±0.3
21	F137V/L138A	73.0±0.3
22	F137V/L138V	71.1±0.5
23	L134V/F137A	73.8±0.2
24	F137V/L138V/I460V	70.7±0.6
25	F137A/L138V/I460V	72.3±0.2
26	F137A/L138A/I460V	69.8±0.5
27	F137A/L138A/I460A	62.1±0.7
28	F137A/L138V/I460A	52.2±0.9
29	F137A/S203A/I460V	72.2±0.2

As it can be seen in **Table 1**, the mutants showed different degrees of thermal stability. The melting temperature of the native enzyme was recorded at 75 °C. *PcPAL* F137A showed an unfolding at a slightly higher temperature compared to the *wild-type* enzyme (76 °C vs. 75 °C), indicating an improved thermostability, although not statistically significant.

T_m values of mutants F137V-, F137A-, I460V- and F137A/I460V- *PcPAL* were lower only by 2-3 °C than the *wt-PcPAL* control, these being the most active enzymes in transforming the tested substrates.

Instead, mutants I460A-, F137A/I460A-, F137V/I460A- and F137A/L138V/I460A *PcPAL* showed a drastic decrease in thermal stability with a melting temperature by 23-24 °C lower than the control and turned out to be less useful in the biotransformation of unnatural phenylalanine analogs (**Figure 5**).




Figure 5. Thermal unfolding of *PcPAL* variants involving mutation I460A. Melting temperatures (T_m) range from 51 to 52 °C.

Other singular mutations, L134, L138, L206, L256, didn't cause probably a global conformational change of the protein, since T_m values between 69-74 °C are only slightly lower than that of the native enzyme.

I. A.3. Conclusions

A library of 28 mutants of phenylalanine ammonia-lyase from *Petroselinum crispum* have been successfully obtained through site-directed mutagenesis. All the mutants have been expressed and purified to high purity and homogeneity, as demonstrated by SDS-PAGE and size exclusion chromatography.

Differential fluorimetric measurements of single and multiple mutations containing the I460A residue, revealed a significant decrease in T_m (51 °C) compared to *wild-type PcPAL* (75.1 °C \pm 0.2). The most active *PcPAL* mutant variants have a thermal stability in a high range of 72-76 °C.

Subchapter B. Obtaining mutant *PcPAL* variants without hexa histidine-tag in order to crystallize the protein in its most natural form

I. B.2. Results and discussion

I. B.2.1. Site-directed mutagenesis, plasmid isolation and the required transformations

Based on the pET15b_*PcPAL* template, with a cleavage site for the endopeptidase TEV, we tried to obtain four different types of mutants. The mutagenic primers used were the same as in case of pET19b_*PcPAL* template.

The main purpose of this section is to obtain mutant *PcPAL* enzymes with removable 6xHis-tag.

The recombinant *PcPAL* encoded in plasmid construct pET19b_*PcPAL*, contains an additional *N*-terminal 21 amino acids long sequence, including the 6xHis-tag, which might affect the protein folding. Therefore, for crystallization studies, we considered the development of recombinant *PcPAL*s with removable *N*-terminal His-tag, more resembling the original protein sequence.

After the expression, purification and the TEV mediated removal of 6xHis-tag, the *wt*- and mutant *PcPAL*s will be used for the crystallization of phenylalanine ammonia-lyases in the presence of several synthetic phenylalanine analogs or the corresponding cinanamates (for example, styryl-, 4-methoxyphenyl-, 4-nitrophenyl-, naphthalen-2-yl- or biphenyl-4-yl-), which were accepted as substrates by *PcPAL* mutants, but not by *wt*-*PcPAL*. These results will provide information about the enzyme-substrate interactions.

I. B.2.3. Expression and purification of TEV S219V enzyme

The steps of enzyme expression and purification were monitored by SDS-PAGE method.

The TEV enzyme having a molecular weight of approximately 29 kDa was eluted with 300 mM-1M imidazole. As it can be observed on column 9 of gel 2, the enzymatic solution after dialysis has a high purity (~ 90% on SDS-PAGE) - **Figure 6**.




Figure 6. SDS-PAGE 10%, gel containing samples from the optimization of the purification steps of **TEV S219V**: **1** – fraction eluted with 100 mM imidazole, **2** – fraction eluted with 200 mM imidazole, **3** – fraction eluted with 300 mM imidazole, **4** – fraction eluted with 400 mM imidazole, **5** – fraction eluted with 500 mM imidazole, **6** – fraction eluted with 1M imidazole, **7** – marker, **8** – the mixture of fractions **2**, **3**, **4** and **5** before dialysis, **9** – the point **8** after dialysis.

Therefore, the enzyme was expressed in a large amount (2 mg/mL) and used immediately to remove histidine labels of *wt*-*PcPAL* and *PcPAL* mutants or was stored at -80 °C in 20% glycerol until further use.

I. B.2.4. The removal of 6xHis-tag through digestion with TEV S219V

The removal of the affinity tag was carried out at 4 °C, using 2 mg of *PcPAL* enzyme and 0.2 mg of enzyme TEV were added in a final volume of 2 mL of Tris buffer (50 mM Tris and 300 mM NaCl, 20% glycerol, pH 8.0) without stirring. The *PcPAL* without His-tag was purified by Ni-affinity column, with a yield of 50-55%, followed by dialysis in 20 mM Tris and 100 mM NaCl, pH 8.0.

I. B.2.5. Analysis of the protein oligomerization by steric exclusion chromatography

Using a Superdex 200 5/150 GL column the oligomerization state⁹ of the enzymes was verified. The elution profile for mutant proteins can be seen in the chromatograms below (**Figure 7**). According to the equation in the calibration curve the signal between 1.4-1.6 mL, where the maximum intensity is at 1.49 mL, corresponds to the tetrameric *PcPAL* enzyme with a molecular weight of 320 kDa.




Figure 7. Representative chromatogram of the enzyme after the dialysis and concentration step using Superdex 200 5/150 GL size-exclusion column: **A)** *wt-PcPAL* without His-tag (10 mg/mL) and **B)** *PcPAL* F137A/I460V without His-tag (8 mg/mL).

I. B.2.6. Analyzing the thermal unfolding of *PcPAL* mutants without the 6×His label.

The unfolding of *PcPAL* wild-type and *PcPAL* mutant (I460V, F137A, F137A/I460V and Y110F/F137/I460V) proteins devoided of their 6×His-tag was performed in the range of 73-74.6 °C, where *PcPAL* *wt* and *PcPAL* F137A had a T_m value lower by 2 °C than the protein counterparts with hexa histidine tag.

Table 2. Melting temperatures (T_m) of *wt*- and I460V-, F137A-, F137A/I460V- and Y110F/F137/I460V-*PcPAL*.

Nr.	<i>PcPAL</i>	T_m (°C)
1	native (<i>wt</i>)	73.0±0.2
2	I460V	74.2±0.5
3	F137A	74.6±0.5
4	F137A/I460V	73.7±0.2
5	Y110F/F137A/I460V	73.5±0.2

I. B.3. Conclusions

The expression, purification and the removal of *N*-terminal 6xHis-tag has been successfully achieved in case of *wt*- and several mutant *PcPAL*s, obtaining protein fractions with high degree of purity and homogeneity. No significant changes in the thermal stability of these enzymes after removing the affinity tag.

The purified, recombinant *PcPAL*s without the label 6×His label allowed the initiation of proteins crystallization experiments with different ligands.

Subchapter C. Expression and purification of novel MIO enzymes from *Pseudomonas fluorescens* R124

I. C.2. Results and discussion

I. C.2.1. Expression and purification of aromatic phenylalanine 2,3-aminomutase (PAM), phenylalanine/histidine or tyrosine ammonia-lyase (XAL) and histidine ammonia-lyase (HAL) all isolated from *Pseudomonas fluorescens* R124

I. C.2.1.1. Expression and purification of PAM, XAL and HAL

Using the general method for fermentation, isolation and purification of MIO enzymes the *Pf*HAL, *Pf*XAL and *Pf*PAM proteins with the *N*-terminal His-tag were obtained and stored in aqueous solution with 15% glycerol at -20 °C without losing their activity.

The purity of all enzymes was verified using a 12% polyacrylamide gel (**Figure 8**).

For each enzyme the fractions eluted from Ni-NTA, corresponding to the pronounced bands around 60 kDa, were analyzed also by size exclusion chromatography, in order to check the protein homogeneity (**Figure 9**). All the expressed and isolated enzymes showed a high degree of purity and homogeneity ~ >85%.¹¹

Molecular weight of MIO enzymes was determined based on the calibration curve determined in advance (**Table 3**).




Figure 8. SDS-PAGE gel of samples from the purification steps of *Pf*XAL. **1** – supernatant after centrifugation of the lysate, **2** – flow-through after application of supernatant on the Ni-NTA column, **3** – fraction eluted with a weak saline solution (30 mM KCl and 50 mM HEPES), **4** – fraction eluted with 300 mM imidazole, **5** – fraction eluted with 50 mM imidazole, **6** – dialyzed, **7** – dialyzed, **8** – fraction eluted with 1 M imidazole, **9** – marker.




Figure 9. Representative chromatogram of *Pf*HAL, purification step using Superdex 200 5/150 GL size-exclusion column. The fraction with a retention volume of 1.2-1.45 mL represents the aggregated forms of the isolated enzyme, while the fraction with 1.5-1.8 mL represents the tetrameric form.

Table 3. MIO enzyme parameters obtained from the calibration curve and steric exclusion chromatography analysis using the Superdex 200 150/5 GL column.

Code	Experimentally determined molecular weight (Daltons)	Calculated molecular weight of tetramer (Daltons)	Calculated molecular weight of monomer (Daltons)
<i>Pf</i> HAL	204046	222000	55500
<i>Pf</i> XAL	211948	228000	57000
<i>Pf</i> PAM	228681	233600	58400

I. C.2.2. Melting temperatures (T_m) of *Pf*HAL, *Pf*XAL and *Pf*PAM enzymes

Table 4. Melting temperatures (T_m) of *Pf*HAL, *Pf*XAL and *Pf*PAM

Enzyme	T_m (°C)
<i>Pf</i> PAM	81.8 ±0.3
<i>Pf</i> XAL	87.0±0.4
<i>Pf</i> HAL	not detectable (>90)

I. C.3. Conclusions

The MIO enzymes, phenylalanine 2,3-aminomutase (PAM), phenylalanine/histidine or tyrosine ammonia-lyase (XAL) and histidine ammonia-lyase (HAL) identified in the genome of the bacterium *Pseudomonas fluorescens* R124 were successfully expressed and isolated using the *Escherichia coli* Rosetta strain cells (DE3) pLyS.

CHAPTER II. Chemical synthesis and biotransformations mediated by *wt*- and *PcPAL* mutant variants


Subchapter A. Chemical synthesis of styrylalanines as novel substrates for phenylalanine ammonia-lyase

II. A.2. Results and discussion

II. A.2.1. Chemical synthesis of styrylalanine substrates *rac*-1a-d and 2a-d

Starting from the commercially available aldehydes **11a-d** acrylic esters **10a-d** were obtained through Wittig reaction, which by reduction with DIBAL-H afforded the derivatives **8a-d**. Further oxidation with manganese-dioxide, followed by another Wittig reaction with triphenyl-phosphoylide afforded **4a-d**, which finally through mild alkaline hydrolysis yielded the styrylic acrylate **2a-d**.

The styrylic alcohols **8a-d** were converted into the diethyl-acetamido malonate derivatives **7a-d** via malonic acid coupling of brominated compounds **9a-d**. Then, through a mild alkaline hydrolysis of **7a-d** followed by the subsequent decarboxylation of **5a-d**, the *N*-acylated amino acids *rac*-**3a-d** were obtained. Finally, deprotection of *rac*-**3a-d** afforded the racemic amino acids *rac*-**1a-d**. (Scheme 1).



Scheme 1. Synthesis of (2*E*,4*E*) styrylacrylates **2a-d**. Reagents and conditions: **I.** $\text{Ph}_3\text{P}=\text{CH}-\text{CO}_2\text{Et}$, toluene, reflux, 24 h; **II.** DIBAL-H/ CH_2Cl_2 at -60°C , 1 h; **III.** $\text{MnO}_2/\text{CH}_2\text{Cl}_2$, RT, 48 h; **IV.** $\text{Ph}_3\text{P}=\text{CH}-\text{CO}_2\text{Et}$, toluene, reflux, 24 h; **V.** 10% KOH, reflux, 20 h. Synthesis of racemic styrylalanines *rac*-**1a-d**. Reagents and conditions: **VI.** $\text{Ph}_3\text{P}=\text{CH}-\text{CO}_2\text{Et}$, $\text{C}_4\text{H}_4\text{BrNO}_2/\text{CH}_2\text{Cl}_2$, 25°C , 2 h; **VII.** NaH, $\text{CH}_3\text{CONHCH}(\text{COOEt})_2/\text{DMF}$, 60°C , 3 h; **VIII.** 10% NaOH in water/MeOH, 60°C , 5 h; **IX.** toluene, reflux, 20 h; **X.** dioxane/18% HCl, reflux, 4 h.

II. A.3. Conclusions

The chemical synthesis of styrylic acrylates **2a-d** and of the corresponding racemic amino acids *rac*-**1a-d** were performed successfully. In further experiments they are used in the ammonia elimination and ammonia addition reactions mediated by *PcPAL* and its F137X mutant variants.

Subchapter B. Inclusion of styryl-alanines in the substrate domain of *PcPAL* through rational design driven protein engineering.


II. B.2. Results and discussion

II. B.2.1. Initial studies on the activity of *PcPAL* and its F137X mutant variants towards styrylalanines

Knowing the ability of *PcPAL* enzymes to accept a wide range of (hetero)arylalanines, we first focused on testing the *wt-PcPAL* on styrylalanines (*rac*-**1a-d**), in order to expand the substrate scope of this enzyme towards compounds with side chains of extended length.

In the first step, a Michaelis-Menten kinetics was measured for the deamination reaction of styrylalanines L-**1a-d** catalyzed by *wt-PAL*. The reaction rate was determined by monitoring the product formation (*2E, 4E*)-5-phenylpenta-2,4-dienoic acid (**2a**), using both UV spectroscopy and HPLC chromatography. Moreover, the presence of the reaction product **2a** in the reaction medium was confirmed also by ¹H-NRM spectroscopy.

The k_{cat} value for the ammonia elimination reaction from L-**1a** was **14** times smaller than the k_{cat} measured for the natural substrate (L-Phe), while the k_{cat}/K_M value for the deamination reaction of L-**1a** was **777** times smaller than the calculated value for the deamination of L-Phe (**Table 5**).



Scheme 2. (A) Synthesis of enantiomerically pure styrylalanines D-**1a-d** by deamination reaction of *rac*-**1a-d** and (B) L-**1a-d** by ammonia addition on styrylacrylates **2a-d**, with *wt*- and mutant *PcPAL*s as biocatalysts.

Molecular data provided an explanation for the low enzymatic activity towards the new substrate: the detrimental interaction between the aromatic ring of the *N-MIO-L-1a*

reaction intermediate and the phenyl group of the amino acid F137, phenylalanine, which is part of the aromatic binding pocket of the *wild-type* enzyme.

Panels A and B from **Figure 10** illustrate three possible arrangements of the reaction intermediate *N*-MIO-L-**1a**, two of which are apparently active and resemble the binding of the natural substrate, phenylalanine, to the active site of *PcPAL*.⁵

Thus, the (*2E,4E*)-diene product can be obtained from the two *N*-MIO intermediate conformers, namely from the *s-cis* [referred to as *pro-s-cis* (*psc*)] – abbreviated L-**1a**_{psc} – and *s-trans* [referred to as *pro-s-trans* (*pst*)] – abbreviated L-**1a**_{pst}, respectively. From the third conformer, (L-**1a**_u) illustrated in **panel B**, which adopts a more relaxed arrangement, that experiences less strain from the F137 side chain, the (*2Z, 4E*)-5-phenylpenta-2,4-dienoic acid can be obtained. Unfortunately, this species could not be detected in the reaction mixture. Thus, L-**1a**_u may be considered an unproductive state.




Figure 10. Models of the three major conformers of the L-**1a** – *N*-MIO reaction intermediate within the active center of *wt-PcPAL*. Colors illustrate the contributions of various atoms to the total energy of the system with green indicating a beneficial contribution (≤ -5 kcal mol⁻¹) and red denoting a detrimental contribution (≥ 2 kcal mol⁻¹). (A) The two conformations that presumably exhibit catalytic activity: L-**1a**_{psc}, enabling the formation of the product **2a** in the *s-cis* (synperiplanar) conformation and L-**1a**_{pst}, enabling the synthesis of the product **2a** in the *s-trans* (antiperiplanar) arrangement. (B) The L-**1a**_u conformation appears to exhibit no catalytic activity as compared to the L-**1a**_{psc} conformation.

Consequently, the above-mentioned results indicate that the clashes manifested between the aromatic ring of the *N*-MIO-L-**1a** intermediate and the F137 residue are responsible for the decrease in the reaction rate.

In order to expand the hydrophobic binding pocket of the *wild-type* enzyme and therefore, loosen up the interaction between the *N*-MIO-L-**1a** reaction intermediate and F137, this amino acid was replaced, in turn, by smaller hydrophobic amino acid residues, namely valine, alanine and glycine. The design of *PcPAL* mutants F137V, F137A and F137G, respectively, was justified also by the fact that F137X-*PcPAL* mutants have proven to be highly efficient biocatalysts in the amination reactions of several *para*-substituted cinnamates.⁴

II. B.2.2. Enzyme kinetics

The catalytic efficiency or the specificity constant of an enzyme is given by the k_{cat}/K_M ratio indicating the efficiency of the biocatalyst towards natural/non-natural substrates or competing substrates.¹²

The catalytic efficiency of the *wild-type* enzyme and its mutant forms towards L-Phe and L-**1a** substrates is presented in **Table 5**.

In the deamination reaction of L-**1a** substrate, F137V-*PcPAL* had a remarkable catalytic efficiency, with the k_{cat}/K_M ratio being 240 times larger than the one calculated in case of *wt-PcPAL*.

Table 5. Kinetic parameters for ammonia elimination reactions with *wt-PcPAL* and F137X-*PcPAL* mutants for L-phenylalanine and for L-styrylalanine (L-**1a**).

<i>PcPAL</i>	L-phenylalanine			L-styrylalanine		
	K_M (μM)	$k_{\text{cat}} \times 10^{-3}$ (s^{-1})	$k_{\text{cat}}/K_M \times 10^{-3}$ ($\text{nM}^{-1} \text{s}^{-1}$)	K_M (μM)	$k_{\text{cat}} \times 10^{-3}$ (s^{-1})	$k_{\text{cat}}/K_M \times 10^{-3}$ ($\text{nM}^{-1} \text{s}^{-1}$)
<i>wt</i>	83 ± 5	694 ± 20	8361 ± 291	4384 ± 158	47.1 ± 0.3	10.7 ± 0.4
F137V	86 ± 10	173 ± 1	2011 ± 131	186 ± 6	422 ± 28	2269 ± 168
F137A	1732 ± 15	283 ± 1	163 ± 2	1173 ± 70	132 ± 2.6	112.5 ± 7.2
F137G	4969 ± 153	52 ± 3	10.4 ± 0.9	4120 ± 270	34.5 ± 3.8	8.3 ± 0.2

Table 6. Kinetic parameters for the ammonia elimination reactions with *wt*- and F137V-*PcPAL*s for racemic styrylalanines *rac-1a-d*.

Substrate	<i>wt-PcPAL</i>			F137V- <i>PcPAL</i>		
	K_M (μM)	$k_{\text{cat}} \times 10^{-3}$ (s^{-1})	$k_{\text{cat}}/K_M \times 10^{-3}$ ($\text{nM}^{-1} \text{s}^{-1}$)	K_M (μM)	$k_{\text{cat}} \times 10^{-3}$ (s^{-1})	$k_{\text{cat}}/K_M \times 10^{-3}$ ($\text{nM}^{-1} \text{s}^{-1}$)
<i>rac-1a</i>	395 ± 6	6.2 ± 0.7	15.6 ± 0.9	201 ± 12	276 ± 13	1373 ± 97
<i>rac-1b</i>	154 ± 7	0.24 ± 0.01	1.5 ± 0.03	78.3 ± 2	78.6 ± 4.4	1004 ± 86
<i>rac-1c</i>	28 ± 1	0.34 ± 0.02	12.1 ± 0.6	94.7 ± 2	156.7 ± 0.02	1667 ± 10
<i>rac-1d</i>	287 ± 3	3.2 ± 0.03	11.1 ± 0.5	326 ± 10	9.9 ± 0.01	30.2 ± 1.9

When using L-**1a** as substrate, the mutant F137V-*PcPAL* showed a 9-fold increase in k_{cat} , while the F137A-*PcPAL* mutant showed a 2,8-fold increase in k_{cat} when compared to *wt-PcPAL*. The F137G mutation proved to be inefficient from an enzymatic catalytic capacity point of view.

As it can be seen in **panel A, Figure 10**, in the active site of the native enzyme the aromatic moiety of the *N*-MIO – L-**1a**_{p_{sc}} intermediate is forced towards the I460 residue, causing its conformational change. In turn, this local conformational change can reshape the whole active site, which could lead to the decrease of the energy level of *N*-MIO-L-**1a**_{p_{sc}} reaction intermediate. Due to F137V mutation, the styryl residue is more relaxed and thus, the energy level of the reaction intermediate is lower. The F137V mutation does not influence the spacial display of the alanine residue of L-**1a** within the catalytic site of F137V-*PcPAL* enzyme as against to *wt-PcPAL*.

II. B.2.3. Kinetic resolution and synthetic applications

The promising enzyme kinetics measurements of L-**1a** deamination, but also the molecular data obtained this far regarding the energy level of *N*-MIO-L-**1a** reaction intermediate, have qualified F137V-*PcPAL* mutant as an efficient biocatalyst for preparative scale production of enantiopure styrylalanines. (**Panel A, Figure 10**).

The styrylalanines *rac-1a-d* were all accepted as substrates in the ammonia elimination reactions in the presence of *wt-PcPAL* or F137V-*PcPAL*. Unfortunately, these

biocatalysts were inactive in the reverse ammonia addition reactions of styrylacrylates **2a-d**. Consequently, emphasis is placed on the ammonia elimination reaction from the racemic styrylalanines.

The kinetic parameters for the ammonia elimination reaction of *rac-1a-d* with *wt*- and F137V-*PcPAL* were determined by UV-based enzymatic assays of styryl acrylates products accumulation in time (**Table 7**).

In all cases, the F137V-*PcPAL* mutant proved to be a superior alternative to the *wild-type* enzyme, the *turnover number* (k_{cat}) and specificity constant (k_{cat}/K_M) values being significantly enhanced for the mutant-mediated reactions in comparison with the *wild-type* enzyme (**Table 7**).

In order to confirm the synthetic usefulness of F137V-*PcPAL* mutant for the kinetic resolutions (KRs) of racemic styrylalanines *rac-1a-d*, the deamination reactions were tested on a semi-preparative scale starting from a 0.1 mmol to a 5 mM substrate concentration with 0.5-1 mg purified *wt*- and F137V-*PcPAL* enzyme (**Table 7**).

Table 7. Conversion of styrylalanines *rac-1a-d* and enantiomeric excess of the products D-**1a-d** in the ammonia elimination reactions catalyzed by *PcPAL* variants.

Entry	<i>PcPAL</i>	Substrate	Time (h)	<i>c</i> (%)	<i>ee</i> _{theor} (%) ^a	<i>ee</i> _{obs} (%)
1	F137V	<i>rac-1a</i>	24	50	100	>99
2		<i>rac-1b</i>	274	50	100	>99
3		<i>rac-1c</i>	134	50	100	>99
4		<i>rac-1d</i>	300	50	100	>99
5	<i>wild-type</i>	<i>rac-1a</i>	274	50	100	>98
6		<i>rac-1b</i>	504	29	41	41
7		<i>rac-1c</i>	600	36	56	55
8		<i>rac-1d</i>	600	31	45	41

^a $ee_{theor} = c/(1-c)$ for a fully selective kinetic resolution

In **Figure 11**, the time conversions of the racemic styrylalanines *rac-1a-d* are presented, while the enantiomeric excess (*ee*) values for the D-**1a-d** compounds, corresponding to the ammonia elimination reactions catalyzed by the two *PcPAL* (mutant and native) are listed in **Table 7**. After each 48 hours, a new batch of enzyme was added to the reaction mixture, compensating the enzyme inactivation in the applied reaction conditions. In all cases, the reaction progress was monitored by HPLC.




Figure 11. Comparative time profiles of conversions of *rac-1a-d* in the ammonia elimination reactions catalyzed by *wt-PcPAL* (dashed lines) and F137V-*PcPAL* (continuous lines).

The obtained time course profile of the conversion of *rac-1a-d* (**Figure 11**) also supported the catalytic superiority of the F137V-*PcPAL* mutant compared to the *wild-type* enzyme, a characteristic that had also been confirmed by Michaelis-Menten kinetic measurements.

In the presence of F137V-*PcPAL* enzyme, an exclusively enantioselective kinetic resolution with a conversion of ~ 50% was achieved after 24 hours in case of *rac-1a*, after 134 hours for *rac-1c* or after a longer period of time for *rac-1b,d* substrates (274 hours and 300 hours, respectively).

Wt-PcPAL proved to be efficient only for the kinetic resolution of *rac-1a* (**Table 7, Entry 5**). As for substituted styrylalanines *rac-1b-d*, the activity of the same enzyme was too low, and moderate conversion values were registered even after longer reaction times (**Figure 11, Table 7, Entries 6-8**).

It is important to note the fact that the stereoselective aspect of L-**1a-c** biotransformations was preserved, and the values of the enantiomeric excess for D-**1a-c** at a given conversion were in accordance with the theoretical values corresponding to the measured conversion, as regard to the initial *rac-1a-d* concentrations.

In case of D-**1d** fraction obtained using the *wt-PAL*, the enantiomeric excess was lower than its theoretical value, thus in accordance with the results that demonstrate the low stereoselectivity of various phenylalanine ammonia-lyases in the synthesis of both nitrophenylalanine enantiomers.

It should be emphasized that, in the case of *rac-1a-d* substrates catalyzed by F137V-*PcPAL*, the compounds D-**1a-d** were obtained with enantiomeric excesses higher than 99%. This result is supported by the obtained time course profiles of conversions, which asymptotically reach the value of 50%.

Therefore, F137V-*PcPAL* proved to be an active and stereoselective biocatalyst for the synthesis of D enantiomers of styrylalanines.

Comparing the kinetic data obtained in the *wt-PcPAL* and F137V-*PcPAL* catalyzed reactions using as substrates L-**1a** (**Table 5**) and *rac-1a* (**Table 6**) respectively, as substrates, it can be concluded that ammonia elimination from L-**1a** styrylalanine is inhibited by the presence of the D-amino acid in both catalysed reactions.

If D-**1a** would not be a competitive inhibitor for the two enzymes, then the apparent K_M of the racemate *rac-1a* would be comparable to the K_M of the L-**1a** enantiomer, while the calculated k_{cat} value would be similar in both cases.

However, the registered kinetic data in the presence of *wt-PcPAL* show a decrease by an order of magnitude of the K_M value and a 7.6-fold decrease of v_{max} and implicitly k_{cat} , when the enzyme is incubated with *rac-1a* instead of L-**1a**.

These differences become less significant when F137V-*PcPAL* is used, with k_{cat} showing only a 1.5-fold decrease when the enzyme is incubated with *rac-1a* instead of L-**1a**. Experimental data obtained for the semipreparative scale synthesis of D-**1a-c** mediated by F137V-*PcPAL*, with an ee >99% at conversions of 50% with regard to the starting materials *rac-1a-c* (**Table 7**), certifies the fact that D-**1a-c** were not processed by the enzyme. This fact suggest that D-**1a**, and also probably D-**1b-d**, act as reversible inhibitors, forming an unproductive D-**1a-d**-N-MIO-F137V-*PcPAL* reaction intermediate.

Molecular modelling data confirm the possible formation of D-**1a**-N-MIO intermediate. Overlaid structures of L-**1a**_{pst} - N-MIO and unproductive covalent intermediate D-**1a** - N-MIO within the active site of *wt*-PcPAL are presented in **Panel B, Figure 12**.




Figure 12. Arrangements of **1a**-N-MIO covalent reaction intermediates in the active site of PcPAL variants. **(A)** The L-**1a**_{psc}-N-MIO conformer shown in the active site of all *wt*-PcPAL și F137V-PcPAL. The differences in the arrangement of the I460 residue in both enzymes can be observed. **(B)** The contrast between the arrangement of the covalent unproductive *wt*-PcPAL-D-**1a** complex (shown in green) and that of the covalent productive *wt*-PcPAL – L-**1a**_{psc} complex (shown in purple).

II. B.2.5. The ammonia addition of styrylacrylates **2a-d** mediated by PcPAL for the synthesis of L-arylalanines

Styrylacrylates **2a-d** were not accepted as substrates in enzymatic ammonia addition reaction neither by *wild-type* or mutant enzyme variants. The products **1a-d** could not be detected by HPLC even after 20 days reaction time.

Molecular modelling studies could not offer an undeniable explanation of the experimental results. Plausible causes could be: poor ligand affinities of **2a-d** to the enzyme or their binding to the catalytic site in unproductive states.

The poor binding of styrylic acids to the catalytic site of *wt*-PcPAL, but much stronger in case of F137V-PcPAL, was confirmed by calculated relative binding energies.

Molecular modelling has also revealed that, regardless of the enzyme used, unproductive energetically favorable conformers have greater binding affinity in comparison with the supposed reactive, but energetically unfavorable, conformers of **2a-d**.

II. B.3. Conclusions

Michaelis-Menten kinetics showed that the value of k_{cat} for the ammonia elimination reaction of L-styryl-alanines L-**1a** using the *wt*-PcPAL enzyme was 14 times lower than the k_{cat} obtained for same reaction but in presence of the natural substrate (L-Phe), while the k_{cat}/K_M value for the deamination reaction of L-**1a** was 777 times smaller than the corresponding value for the deamination of L-Phe.

Molecular data have illustrated three possible arrangements (L-**1a**_{psc}, L-**1a**_{pst} - active state and L-**1a**_u - unproductive state) of the N-MIO - L-**1a** reaction intermediate in the active site of *wild-type* enzyme, and highlighted the repulsion between the phenyl ring of the N-

MIO - L-1a intermediate and the phenyl group of the amino acid phenylalanine F137 from the hydrophobic pocket of the catalytic site of *wild-type* enzyme.

It has been concluded that this interaction is responsible for the decrease of the reaction rate displayed by *wt-PcPAL* to **L-1a**.

Replacement of the residue F137 with smaller hydrophobic amino acids (valine, alanine and glycine), led to an enlargement of the hydrophobic binding pocket of the native enzyme and consequently, to the increase of the affinity of the mutant enzyme towards **L-1a**. The mutant F137V-*PcPAL* proved to be the most efficient biocatalyst for the removal of ammonia from styrylalanine **L-1a**, but also from *rac-1a-d*.


Nevertheless, neither *wild-type* enzyme or its mutant variants were active in the ammonia addition reactions to (*E*)-styrylacrylates **2a-d**. It is presumed that the main reason for this drawback lies in the formation of unproductive binding states of compounds **2a-d** in the enzymatic catalytic site.

Subchapter C. Tailored mutants of phenylalanine ammonia-lyase from *Petroselinum crispum* for the synthesis of bulky L- and D-arylalanines

II. C.2. Results and Discussion

II. C.2.1. Rational design, stability and activity of mutant *PcPAL*s

Some substrates, namely styryl (**2a**), 4-methoxyphenyl (**2e**), naphthalen-2-yl- (**2f**) and biphenyl-4-yl (**2g**) acrylic acid presented in **Scheme 3**, were previously tested with *wild-type PcPAL*, but the conversions achieved were either very low or nonexistent or the target compounds proved to be enzyme inhibitors.^{4, 5, 14, 15}



Scheme 3. The ammonia elimination (A) and ammonia addition (B) reactions tested using *PcPAL* variants.

In the second subchapter we witnessed that in the ammonia addition reaction no *PcPAL* mutant variants are known to exhibit such activity, except in case of the styrylalanines deamination where mutant F137V showed activity.⁵

In order to obtain PAL biocatalysts capable of transforming a series of bulky and sterically demanding valuable L- and D-arylalanines, we focused on the mutational analysis and rational design of the hydrophobic binding pocket to *PcPAL*.

According to earlier reported substrate domain expansion of PAL enzymes based on steric clash reduction concepts,^{4,5} we selected several amino acids residues from the hydrophobic binding site of *Petroselinum crispum* PAL, namely L134, F137, L138, L206, L256 and I460 residues (highly conserved residue) and exchanged them to smaller amino acids such as valine or alanine, in order to obtain both single and double/triple mutants of *PcPAL* (**Figure 13**).




Figure 13. Model of the active center of *PcPAL* with (*E*)-cinnamic acid as a modeled substrate. The distance between the neighboring amino acid side chains and the substrate is less than 5 Å. The positions of these residues relative to the plane of the ligand are differentiated by the use of various colors: **black** and **red** – within, **green** – below and **orange** – above the plane. **MIO** group is above the plane. The hydrophobic amino acids depicted in boxes were replaced either independently or in combination with smaller hydrophobic amino acids, such as valine or alanine.

II. C.2.2. Testing of *PcPAL* single mutant variants in the elimination reaction of arylalanines *rac*-1a,e-l

The activity of the generated *PcPAL* single mutant variants was tested in both ammonia elimination and addition reactions, using arylalanines *rac*-1a,e-l (**Scheme 3A**) and arylacrylates 2a,e-l (**Scheme 3B**) respectively, as substrates. Besides the well-known beneficial effect of the frequently mutated F137 to Ala and Val^{3,5} in the deamination reactions of *rac*-1a,e-l, the importance in changing the highly conserved isoleucine within the hydrophobic pocket (position 460 in *PcPAL*) with less bulkier apolar amino acids V and A was revealed in this thesis.

Thus, I460V/A mutant provided significantly increased catalytic activity towards almost all tested substrates compared to *wild-type* *PcPAL* enzyme (**Table 8**). Moreover, both F137V/A and I460V mutants provided good (c=35% in case of *rac*-1g) to excellent (c=50% in case of *rac*-1a,j,k) conversions after 16 h. Unfortunately, there was one substrate, namely *rac*-1l, whose structure resembles the benzo[b]furan-3-yl- and benzo[b]thiophene-3-yl alanines,¹⁶ the *wt*-PAL-inhibitors, that still behaved as a competitive inhibitor for both *wild-type* and mutant variants.

Surprisingly, F137A-*PcPAL* turned out to be active in the ammonia elimination reaction of *rac-1l*, but regrettably with very low conversion (c=6%) even after a longer reaction time.

Table 8. The ammonia elimination reactions of *rac-1a,e-l* – conversions of the best *PcPAL* mutants compared to the *wild-type* (*wt*) *PcPAL*.

Substrate	Ar. group	<i>PcPAL</i> variant ^[a]	c (%)	Substrate	Ar. group	<i>PcPAL</i> variant ^[a]	c (%)
<i>rac-1a</i>	styryl	<i>wt</i>	<1	<i>rac-1i</i>	5-phenylthiophen-2-yl	<i>wt</i>	<1
<i>rac-1a</i>	styryl	I460V	~50	<i>rac-1i</i>	5-phenylthiophen-2-yl	F137V	35
<i>rac-1a</i>	styryl	F137V	~50	<i>rac-1i</i>	5-phenylthiophen-2-yl	F137A	44
<i>rac-1e</i>	4-methoxy	<i>wt</i>	3	<i>rac-1j</i>	2'-chloro-5-phenylthiophen-2-yl	<i>wt</i>	<1
<i>rac-1e</i>	4-methoxy	F137V	37	<i>rac-1j</i>	2'-chloro-5-phenylthiophen-2-yl	F137V	19
<i>rac-1e</i>	4-methoxy	I460V	39	<i>rac-1j</i>	2'-chloro-5-phenylthiophen-2-yl	F137A	~50
<i>rac-1f</i>	naphthalen-2-yl	<i>wt</i>	6	<i>rac-1k</i>	4'-chloro-5-phenylthiophen-2-yl	<i>wt</i>	<1
<i>rac-1f</i>	naphthalen-2-yl	I460V	37	<i>rac-1k</i>	4'-chloro-5-phenylthiophen-2-yl	I460V	10
<i>rac-1f</i>	naphthalen-2-yl	F137V	39	<i>rac-1k</i>	4'-chloro-5-phenylthiophen-2-yl	F137A	~50
<i>rac-1g</i>	biphenyl-4-yl	<i>wt</i>	<1	<i>rac-1l</i>	2-phenylthiazol-4-yl	<i>wt</i>	<1
<i>rac-1g</i>	biphenyl-4-yl	I460V	8	<i>rac-1l</i>	2-phenylthiazol-4-yl	F137A	6
<i>rac-1g</i>	biphenyl-4-yl	F137A	15	[a] <i>PcPAL</i> variant: 50 µg; reaction volume: 500 µL; reaction medium: Tris-buffer (100 mM Tris.HCl, pH 8.8, 20 mM β-cyclodextrin), substrate concentration: 1 mM; reaction time: 16 h			
<i>rac-1h</i>	4'-fluorobiphenyl-4-yl	<i>wt</i>	<1				
<i>rac-1h</i>	4'-fluorobiphenyl-4-yl	F137V	37				
<i>rac-1h</i>	4'-fluorobiphenyl-4-yl	F137A	39				

II. C.2.3. Testing of *PcPAL* single mutant variants in the ammonia addition reactions onto **2a,e-l** cinnamic acids

In case of the ammonia addition reactions onto **2a,e-k** cinnamic acid analogues, the single *PcPAL* mutants were, in general, not very active biocatalysts. Still, there were two exceptions, namely the amination of 4-methoxyphenyl- **2e** catalyzed by I460V-*PcPAL* (c=29%) and naphthalen-2-yl-acrylic acid **2f** catalyzed by F137V-*PcPAL* (c=55%) (**Table 9**).

It is notable that, individual mutations of residues L138, L134, L206, L256 to valine or alanine did not improve the catalytic performance of the *wild-type* enzyme in neither of the investigated cases (**Table 9**).

Table 9. Conversion values of the ammonia addition reaction onto **2a,e-l** substrates after 20 h.

Nr.	<i>PcPAL</i>	Conversions (%)								
		2a	2e	2f	2g	2h	2i	2j	2k	2l
1	<i>wild-type</i>	<1	<1	<1	<1	<1	<1	<1	<1	<1
5	F137A	<1	<1	<1	<1	<1	4	<1	<1	<1
6	F137V	<1	26	55	<1	<1	2	<1	<1	<1
14	I460V	<1	29	50	<1	<1	<1	<1	<1	<1
15	F137A/I460V	4	4	9	27	8	6	3	2	<1
16	F137A/I460A	<1	<1	<1	8	<1	<1	<1	<1	<1
17	F137V/I460A	<1	<1	<1	<1	<1	<1	<1	<1	<1
18	F137V/I460V	22	32	39	9	<1	3	<1	<1	<1
19	F137A/L138V	<1	<1	<1	<1	<1	2	<1	<1	<1
24	F137V/L138V/I460V	14	27	21	4	<1	<1	<1	<1	<1
25	F137A/L138V/I460V	<1	3	<1	8	<1	3	<1	<1	<1

^a Single mutants L134A, L134V, F137G, L138A, L138V, L206A, L206V, L256A, L256V, I460A, double F137A/L138A, F137V/L138A, F137V/L138V, L134V/F137A and triple F137A/L138A/I460V, F137A/L138A/I460A, F137A/L138V/I460A proved to be totally inefficient in transforming the substrates **2a,e-l**.

II. C.2.4. Testing of *PcPAL* double and triple mutant variants in the elimination (*rac-1a,e-l*) and addition reactions (**2a, e-l**)

In the ammonia elimination reactions of *rac-1a,e-l*, the double and triple mutants of *PcPAL* managed to improve the conversion values only in case of two substrates: 4'-fluorobiphenyl-4-ylalanine, *rac-1h* (from 15% conversion with F137A-*PcPAL* (**Table 8**) to 39% with F137A/I460V mutant), and 5-phenylthiophen-2-yl-alanine *rac-1i* (from 44% conversion with F137A-*PcPAL* (**Table 8**) to 48% conversion with F137A/L138V mutant).

In case of ammonia addition reactions onto **2a,e-l** acrylates, double mutants of F137V/A showed increased activity in case of **2a** and **2g** (**Table 10**) to whom single mutants proved to be inactive (**Table 9**). This result can be explained by the strong non-additive, cooperative effect⁵ of point mutations of the neighboring residues F137 and I460.

Table 10. Activity of the *wild-type* (*wt*) *PcPAL* compared to the best *PcPAL* mutants in the ammonia addition reaction of **2a,e-l**.

Substrate	R group	<i>PcPAL</i> variant ^[a]	<i>c</i> (%)	Substrate	R group	<i>PcPAL</i> variant ^[a]	<i>c</i> (%)
2a	styryl	<i>wt</i>	<1	2h	4'-fluorobiphenyl-4-yl	<i>wt</i>	<1
2a	styryl	F137V/I460V	22	2h	4'-fluorobiphenyl-4-yl	F137A/I460V	8
2e	4-methoxy	<i>wt</i>	<1	2i	5-phenylthiophen-2-yl	<i>wt</i>	<1
2e	4-methoxy	F137V/I460V	32	2i	5-phenylthiophen-2-yl	F137A/I460V	6
2f	naphthalen-2-yl	<i>wt</i>	<1	2j	2'-chloro-5-phenylthiophen-2-yl	<i>wt</i>	<1
2f	naphthalen-2-yl	F137V	55	2j	2'-chloro-5-phenylthiophen-2-yl	F137A/I460V	3
2g	biphenyl-4-yl	<i>wt</i>	<1	2k	4'-chloro-5-phenylthiophen-2-yl	<i>wt</i>	<1
2g	biphenyl-4-yl	F137A/I460V	27	2k	4'-chloro-5-phenylthiophen-2-yl	F137A/I460V	2

[a] *PcPAL* variant: 50 µg; reaction volume: 500 µL; reaction medium: 6 M NH₃ buffer (pH 10, adjusted with CO₂); substrate concentration: 1 mM; assays were performed in 1.5 mL glass vials sealed with PTFE septum at 30 °C, 200 rpm for 20 h.

Unfortunately, F137A/I460V showed low activity in the presence of **2h-k** (*c*=3-8% after 20 h) (**Table 9**) were observed using F137A/I460V enzyme as biocatalyst. Moreover, using *PcPAL* enzymes with multiple mutations resulted in no significant increase in conversion when compared to the *PcPAL* single mutants in case of **2e** and **2f** arylacrylates (**Table 9**), while **2l** (2-phenylthiazol-4-yl) acrylic acid could not be transformed by neither of these enzymes (**Table 9**).

Combining L138V/A mutation with F137V/A and/or I460 A/V in order to afford double and triple mutants, was unsuccessful in increasing the catalytic activity in either elimination or addition reactions. These results point out the importance of I460 residue in obtaining a *PcPAL* mutant with increased activity and which combined with the mutation of F137 amino acid, may generate valuable biocatalysts in ammonia addition reactions for the production of important L-arylalanines in the synthesis of biologically active compounds.

Once the best mutants were obtained (high conversion values and enantiomeric excess), we further focused our attention on the optimization of the reaction conditions, using as model substrates biphenyl-4-yl-alanine *rac*-**1g** in ammonia elimination reaction and naphthalen-2-yl-acrylic acid **2f** in ammonia addition reaction.

II. C.2.7. Computational results and the thermal unfolding profile of *wild-type PcPAL* and F137A/I460V-*PcPAL* in the presence of high concentrations of ammonia

According to our previously computational analysis, the improved results in conversions and ee in case of L-**1a,e-k** substrates are possible due to the enhanced affinity of the corresponding *PcPAL* mutant variants for these compounds, but also due to a better reaction transition states stabilization, which can be seen in higher turnover numbers.⁵ This increase in substrate affinity was confirmed/analysed by molecular modelling of the *N*-MIO enzyme-substrate covalent reaction intermediate.

Figure 14 illustrates three situations for the increased affinity for L-**1h** of F137A/I460V-*PcPAL* in comparison to *wt-PcPAL*. The binding of L-**1h** substrate to the catalytic site of the native enzyme (**Figure 14A**) and to F137A/I460V-*PcPAL* (**Figure 14C**) are presented. The double mutation led to an increase of the hydrophobic binding pocket of the catalytic site and therefore, the *N*-MIO intermediate is more sterically relaxed.

Figure 14B illustrates an overlapping of the two above described situations, where a visible significant displacement of the biaryllic residue in the expanded hydrophobic pocket of F137A/I460V-*PcPAL* as against to its position, is sterically hindered in the active site of *wt-PcPAL*.

Similar situations have also been reported for L-arylalanines L-**1f-g,i-k**, with the exception of L-**1e**, whose affinity to the enzyme was less affected by the mutations.




Figure 14: Models of L-**1h** - N-MIO reaction intermediates exhibiting catalytic activity, depicted within the native enzyme (**panel A**) and within the mutant variant F137A/I460V-*PcPAL* (**panel C**). Volumes within the mesh illustrate the space available within the active center of the corresponding *PcPAL* variant. Panel **B** depicts a combination of panels **A** and **C**, illustrated with the net for the *wild-type* enzyme only. Mutational sites and substrate arrangements are shown in magenta for the native enzyme and in blue for the F137A/I460V-*PcPAL*. The colored areas of the net depict close interactions with the respective amino acids of the mutational site.

Analyzing the thermal unfolding profile of *wild-type PcPAL* and F137A/I460V-*PcPAL*, a decrease in their thermostability can be observed in the presence of high ammonia concentrations (**Figure 15 and 16**). A decrease of the melting temperature T_m with up to 20 °C was observed in case of the native enzyme and 13 °C in case of the double mutant, when compared to temperatures of 74-75 °C measured for the same enzymes in 0.1 M Tris buffer (**Table 11**).

Enzymes most likely adopt another conformation, a reason why the obtained computational results cannot be correlated with protein thermostability experiments.




Figure 15. Thermal unfolding of F137A/I460V-*PcPAL* in buffers with different ammonia content.




Figure 16. Thermal unfolding of *wt-PcPAL* in buffers with different ammonia content.

Table 11. Melting temperatures (T_m) of *wt*- and F137A/I460V-*PcPAL* variants in buffers with different ammonia concentrations.

Buffer	T_m (°C) <i>wt-PcPAL</i>	T_m (°C) F137A/I460V- <i>PcPAL</i>
0.1 M Tris	75.1±0.2	74.4±0.4
1M NH ₃	68.9±0.2	67.0±0.2
2M NH ₃	64.7±0.5	65.1±0.2
4M NH ₃	55.1±0.5	63.4±0.3
6M NH ₃	54.4±0.9	61.9±0.7

II. C.3. Conclusions

The exchange of only one of the F137 and I460 residues to a smaller hydrophobic amino acid residue provided enhanced catalytic activity of *PcPAL* in the deamination reaction.

Combined mutations of F137 and I460 residues with valine and alanine, with a non-additive favorable effect, allowed the creation of efficient PAL-biocatalysts also for the stereoselective ammonia addition reactions of bulky cinnamic acid analogues.

While the importance of the F137 residue and its modified variants regarding the enzyme's substrate tolerance has been known, the beneficial effect on catalytic activity of mutations of residue I460, and its cooperative, non-additive effect with mutations of F137, is firstly reported.

The developed novel mutants, F137V/A and I460V/A, act as remarkable biocatalysts, facilitating the synthesis of D- and L- enantiomers of bulkier, synthetically valuable phenylalanine analogues, such as (naphthalen-2-yl) alanine **1f** and 4-methoxy-phenylalanine **1e**.

General Conclusions

1. Site-directed mutagenesis was employed in order to successfully obtain a considerable number of *PcPAL* mutant variants. Thermal stability measurements concluded that the T_m was influenced only by I460A mutation ($T_m = 74 \rightarrow 51$ °C), but this did not affect the yield of the catalyzed reaction.
2. *Wt*- and mutant variants (F137A, I460V, F137A/I460V and Y110F/F137A/I460V) of recombinant *PcPAL*s without an *N*-terminal His-tag have been obtained through TEV-protease mediated digestions. The high purity and homogenous recombinant protein samples, resembling the original *PcPAL* sequence, have been used in crystallization studies.
3. The MIO-enzyme collection was expanded with novel recombinant phenylalanine 2,3-aminomutase (PAM), 2,3-aminomutases XAL (phenylalanine/histidine/tyrosine ammonia-lyase) and histidine ammonia-lyase (HAL) originary from *Pseudomonas fluorescens* R124.
4. The chemical synthesis of novel substrates for *PcPAL*, such as the styrylacrylates **2a-d** and their corresponding racemic styrylalanines, *rac*-**1a-d**, was achieved.
5. The molecular modeling data has established the repulsive interactions between the F137 residue of *PcPAL* and the aromatic ring of L-styrylalanine L-**1a** in the case of *N*-MIO-L-1a intermediate formation. A library of F137X-*PcPAL* mutants was created (with X representing valine, alanine or glycine) from which F137V-*PcPAL* mutant turned out to be the most efficient in both the deamination of L-**1a** and of the styrylalanine racemic mixtures *rac*-**1a-d**. In contrast to the native enzyme, F137V-*PcPAL* mutant proved to be a useful biocatalyst for preparative scale synthesis of D-styryl-alanines with high enantiomeric purity.
6. Point mutations were employed in order to obtain a more relaxed enzyme-substrate complex also in the case of bulky analogues of phenylalanine. It was demonstrated that the replacement of F137 and I460 residues with smaller hydrophobic amino acids facilitated the removal of ammonia from bulky arylalanines in a stereoselective manner.
7. For the successful stereoselective ammonia addition on the bulky cinnamic acid analogues, combined mutations of F137 and I460 residues was necessary. Thus, active and stereoselective biocatalysts were developed for the synthesis of D- and L-([1, 1'-biphenyl]-4-yl) and D- 5-phenylthiophen-2-yl) alanines, key intermediates in the synthesis of compounds with pharmaceutical activity.

Selective bibliography

- [1] K. Tujioka, S. Okuyama, H. Yokogoshi, Y. Fukaya, K. Hayase, K. Horie, M. Kim, *Springer-Verlag* **2006**, *32*, 255–260.
- [2] R. Suenaga, S. Tomonaga, H. Yamane, I. Kurauchi, Y. Tsuneyoshi, H. Sato, D.M. Denbow, M. Furuse, *Springer-Verlag* **2007**, *35*, 139–146.
- [3] S. Bartsch, U.T. Bornscheuer, *PEDS* **2010**, *23*, 929–933.
- [4] S.T. Ahmed, F. Parmeggiani, N.J. Weise, S.L. Flitsch, N.J. Turner, *ACS Catal.* **2015**, *5*, 5410–5413.
- [5] L.C. Bencze, A. Filip, G. Bánóczy, M.I. Toşa, F.D. Irimie, Á. Gellért, L. Poppe, C. Paizs, *Org. Biomol. Chem.* **2017**, *15*, 3717–3727.
- [6] Filip A., Nagy E.Z.A., Tork S.D., Bánóczy G., Toşa M.I., Irimie F.D., Poppe L., Csaba P., Bencze L.C., *ChemCatChem.* **2018**, *10*, 2627–2633.
- [7] C. Papworth, J.C. Bauer, J. Braman, D.A. Wright, *Strategies* **1996**, *9*, 3–4
- [8] a) M. Maschberger, H.M. Resch, S. Duhr, D. Breitsprecher **2015** NanoTemper Technologies GmbH; b) Prometheus NT.48 nanoDSF Report, 08.04.2016
- [9] E.R.S. Kunji, M. Harding, P.J.G. Butler, P. Akamine, *Methods* **2008**, *46*, 62.
- [10] L.D. Cabrita, G.Dimitri, A.L. Robertson, Y. Dehouck, M. Rooman, S.P. Bottomley, *Journal List Protein Sci.* **2007**, *16*, 2360–2367.
- [11] P. Csuka, V. Juhász, S. Kohári, A. Filip, A. Varga, P. Sátorhelyi, L.C. Bencze, H. Barton, C. Paizs, L. Poppe, *ChemBioChem.* **2018**, *19*, 1–9.
- [12] R. Eisinger, M.J. Danson, D.W. Hough, *Trends Biotechnol.* **2007**, *25*, 247–249.
- [13] K.R. Hanson, E.A. Havir, *Arch. Biochem. Biophys.* **1970**, *141*, 1–17
- [14] A. Dreßen, T. Hilberath, U. Mackfeld, A. Billmeier, J. Rudat, M. Pohl, *J. Biotechnol.* **2017**, *258*, 148–157.
- [15] W. Liu, US Pat 5,981,239, to Great Lakes Chemical Co. *Chem. Abstr.* **1999**, *131*, 321632.
- [16] C. Paizs, M.I. Toşa, L.C. Bencze, J. Brem, F.D. Irimie, *Heterocycles* **2011**, *82*, 1217–1228